Medicare Part D coverage · ethosuximide · RxCUI 755357

ethosuximide 50 MG/ML Oral Solution [Zarontin]

Per the CMS 2026 Part D formulary file, ethosuximide 50 MG/ML Oral Solution [Zarontin] is covered by 6 Medicare Part D plans (0.1% of enrollable products), averaging Tier 4, with prior authorization required on 0% of covering formularies.

0.1%
Plan coverage
6
Plans covering
T4
Avg tier
0%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for ethosuximide 50 MG/ML Oral Solution [Zarontin]

Per the CMS 2026 Part D formulary file, ethosuximide 50 MG/ML Oral Solution [Zarontin] (RxNorm concept RXCUI 755357, generic name ethosuximide) appears on 1 distinct formulary file spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 4, with a cross-plan average of Tier 4.

Real-world access to ethosuximide 50 MG/ML Oral Solution [Zarontin] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 2,145 Part D beneficiaries filled ethosuximide 50 MG/ML Oral Solution [Zarontin] in 2023, with total plan-and-beneficiary spending of $2,036,964 and an average per-beneficiary annual cost of $949.63. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry ethosuximide 50 MG/ML Oral Solution [Zarontin] today.

Coverage Details

Formularies covering
1
Plans covering
6
Coverage rate
0.1%
Tier range
Tier 4, Non-Preferred
Average tier
Tier 4, Non-Preferred

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
2,145
Total spending
$2,036,964
Avg per beneficiary
$949.63

Tier Distribution Across Plans

6 plans
Tier 4, Non-Preferred

Medicare Advantage Plans (MA-PD) Covering ethosuximide 50 MG/ML Oral Solution [Zarontin]

6 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Óptimo Plus (PPO) Triple S Advantage, Inc. T4 No $0 PR
Contigo Plus (HMO C-SNP) Triple S Advantage, Inc. T4 No $0 PR
Brillante (HMO-POS) Triple S Advantage, Inc. T4 No $0 PR
Enlace Plus (HMO) Triple S Advantage, Inc. T4 No $0 PR
ContigoEnMente (HMO C-SNP) Triple S Advantage, Inc. T4 No $0 PR
Ahorro Plus (HMO) Triple S Advantage, Inc. T4 No $0 PR

Frequently Asked Questions

Is ethosuximide 50 MG/ML Oral Solution [Zarontin] covered by Medicare Part D?

Yes, ethosuximide 50 MG/ML Oral Solution [Zarontin] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).

What tier is ethosuximide 50 MG/ML Oral Solution [Zarontin] on Medicare Part D plans?

ethosuximide 50 MG/ML Oral Solution [Zarontin] averages Tier 4 across Part D plans, ranging from Tier 4 to Tier 4.

Does ethosuximide 50 MG/ML Oral Solution [Zarontin] require prior authorization?

0% of Part D formularies require prior authorization for ethosuximide 50 MG/ML Oral Solution [Zarontin]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on ethosuximide 50 MG/ML Oral Solution [Zarontin]?

In 2023, total Medicare Part D spending on ethosuximide 50 MG/ML Oral Solution [Zarontin] was $2,036,964, covering 2,145 beneficiaries. The average spend per beneficiary was $949.63.

Read our methodology - how this data is sourced, computed, and verified.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Closest average formulary tier

Similar prior-authorization rate

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare